发明授权
US08680091B2 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
失效
6-芳基烷基氨基-2,3,4,5-四氢-1H-苯并[d]吖庚因，为5-HT 2C受体激动剂
![6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists](/docs/US/2014-03-25/US08680091B2/abs.jpg.600x600.jpg)
- 专利标题： 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
- 专利标题（中）： 6-芳基烷基氨基-2,3,4,5-四氢-1H-苯并[d]吖庚因，为5-HT 2C受体激动剂
-
申请号： US13156575申请日： 2011-06-09
-
公开(公告)号： US08680091B2公开(公告)日： 2014-03-25
- 发明人: Karen Briner , Manuel Javier Cases-Thomas , Marta Adeva Bartolome , Christopher Stanley Galka , Alicia Marcos Llorente , Maria Angeles Martinez-Grau , Michael Philip Mazanetz , John Cunningham O'Toole , Richard Edmund Rathmell , Matthew Robert Reinhard , Selma Sapmaz , Andrew Caerwyn Williams
- 申请人： Karen Briner , Manuel Javier Cases-Thomas , Marta Adeva Bartolome , Christopher Stanley Galka , Alicia Marcos Llorente , Maria Angeles Martinez-Grau , Michael Philip Mazanetz , John Cunningham O'Toole , Richard Edmund Rathmell , Matthew Robert Reinhard , Selma Sapmaz , Andrew Caerwyn Williams
- 申请人地址： US IN Indianapolis
- 专利权人： Eli Lilly and Company
- 当前专利权人： Eli Lilly and Company
- 当前专利权人地址： US IN Indianapolis
- 代理商 R. Craig Tucker
- 优先权： EP05380191 20050901
- 主分类号： A61K31/55
- IPC分类号： A61K31/55 ; C07D223/16 ; C07D401/12 ; C07D403/12 ; C07D409/12 ; C07D417/12
![6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists](/abs-image/US/2014/03/25/US08680091B2/abs.jpg.150x150.jpg)
摘要：
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
公开/授权文献
信息查询
